# Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)

> **NCT05509023** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Q32 Bio Inc.** · enrollment: 102 (estimated)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** ADX-914
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05509023
- **Lead sponsor:** Q32 Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-09-30
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2024-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05509023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05509023, "Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05509023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*